.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Federal Trade Commission
Fuji
Covington
Chubb
Argus Health
QuintilesIMS
US Army
Moodys
Merck

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 077273

« Back to Dashboard

NDA 077273 describes TUSSICAPS, which is a drug marketed by Ecr Pharma and is included in one NDA. It is available from two suppliers. Additional details are available on the TUSSICAPS profile page.

The generic ingredient in TUSSICAPS is chlorpheniramine polistirex; hydrocodone polistirex. There are twenty-nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the chlorpheniramine polistirex; hydrocodone polistirex profile page.

Summary for 077273

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 077273

Suppliers and Packaging for NDA: 077273

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TUSSICAPS chlorpheniramine polistirex; hydrocodone polistirex CAPSULE, EXTENDED RELEASE;ORAL 077273 ANDA VALEANT PHARMACEUTICALS NORTH AMERICA LLC 0187-0054 0187-0054-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0187-0054-01)
TUSSICAPS chlorpheniramine polistirex; hydrocodone polistirex CAPSULE, EXTENDED RELEASE;ORAL 077273 ANDA VALEANT PHARMACEUTICALS NORTH AMERICA LLC 0187-0054 0187-0054-20 20 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0187-0054-20)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 8MG MALEATE;EQ 10MG BITARTRATE
Approval Date:Sep 24, 2007TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 4MG MALEATE;EQ 5MG BITARTRATE
Approval Date:Sep 24, 2007TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
US Department of Justice
Farmers Insurance
AstraZeneca
Citi
Deloitte
UBS
Accenture
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot